NGNE250516P25000
- 0.00
- 0.000.00%
Neurogene Newsroom
BMO Capital Maintains Neurogene(NGNE.US) With Buy Rating, Cuts Target Price to $16
Express News | Neurogene : Increases Nomination Threshold at Which Bba Has Certain Rights to Nominate One Person as Director to 14.9% of Voting Stock
Express News | Neurogene Inc - Amends Agreement With Baker Bros to Increase Nomination Threshold - SEC Filing
Neurogene Price Target Cut to $16.00/Share From $45.00 by BMO Capital
Neurogene Is Maintained at Outperform by BMO Capital
Express News | Neurogene Inc : BMO Cuts Target Price to $16 From $45
Top 10 Russell 2000 Weekly Gainers and Losers as Wall Street Crashes
Neurogene Announces Peer-Reviewed Publication Demonstrating Gene Therapy Candidate NGN-401 With EXACT Technology Regulates Transgene Expression On Preclinical Models Of Rett Syndrome
Neurogene Announces Peer-Reviewed Publication Demonstrating Gene Therapy Candidate NGN-401 With EXACT Technology Regulates Transgene Expression in Preclinical Models of Rett Syndrome
Insiders Who Purchased US$1.46m Of Neurogene Stock May Not Have Expected 32% Tumble
12 Health Care Stocks Moving In Monday's Intraday Session
How Peter Marks' FDA Departure Is Impacting Pharma, Biotech Stocks
New Analyst Forecast: $NGNE Given $50.0 Price Target
Stifel Maintains Neurogene(NGNE.US) With Buy Rating, Maintains Target Price $46
TD Cowen Maintains Neurogene(NGNE.US) With Buy Rating
Neurogene Reports 2024 Financial Results and Advances in Rett Syndrome Trial
Neurogene's Promising Clinical Progress and Financial Stability Earns Buy Rating
William Blair Maintains Neurogene(NGNE.US) With Buy Rating
H.C. Wainwright Maintains Neurogene(NGNE.US) With Buy Rating, Cuts Target Price to $50
Baird Maintains Neurogene(NGNE.US) With Buy Rating, Cuts Target Price to $38